American Urological Association (AUA), The Journal of Urology, 3(175), p. 1031-1031, 2006
DOI: 10.1016/s0022-5347(05)00635-x
Springer (part of Springer Nature), World Journal of Urology, 3(23), p. 225-229
DOI: 10.1007/s00345-005-0502-8
Full text: Unavailable
The use of a new tined lead electrode for sacral neuromodulation (SNS) was evaluated in a European study including 127 patients with chronic voiding dysfunction. The tined lead can be implanted during the first stage of the SNS procedure, which makes a longer test period possible before implanting the pulse generator in a second stage. Implantation of the tined lead was performed under local anaesthesia in 89% of patients. Screening lasted on average 30 days. Screening with the tined lead was considered successful by the physicians in 77% of patients (n=72). In 74% of first stage patients (n=70), at least 50% improvement in the main symptoms versus baseline was obtained. This was sustained for up to 6 weeks. All of these patients received the pulse generator in a second stage. The outcome of this study supports the use of the tined lead electrode as a screening tool in SNS therapy.